Algert Global LLC Buys New Shares in Amedisys, Inc. (NASDAQ:AMED)

Algert Global LLC purchased a new position in shares of Amedisys, Inc. (NASDAQ:AMED) in the second quarter, according to its most recent filing with the SEC. The firm purchased 3,292 shares of the health services provider’s stock, valued at approximately $302,000.

A number of other large investors have also recently bought and sold shares of the business. Banque Cantonale Vaudoise bought a new stake in shares of Amedisys during the 1st quarter valued at about $60,000. Innealta Capital LLC acquired a new stake in shares of Amedisys during the 2nd quarter worth approximately $64,000. Covestor Ltd increased its stake in shares of Amedisys by 134.2% in the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after acquiring an additional 447 shares in the last quarter. Signaturefd LLC increased its stake in shares of Amedisys by 88.2% in the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock valued at $104,000 after acquiring an additional 530 shares in the last quarter. Finally, GAM Holding AG acquired a new position in shares of Amedisys during the 2nd quarter valued at $275,000. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMED has been the subject of several research analyst reports. William Blair downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. Deutsche Bank Aktiengesellschaft downgraded Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price for the company. in a research note on Monday, July 29th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research note on Thursday, July 25th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Amedisys currently has a consensus rating of “Hold” and a consensus target price of $100.67.

Amedisys Stock Up 0.5 %

Amedisys stock opened at $96.29 on Wednesday. The firm has a market capitalization of $3.15 billion, a price-to-earnings ratio of -150.45, a price-to-earnings-growth ratio of 1.90 and a beta of 0.78. The firm’s fifty day moving average price is $97.36 and its two-hundred day moving average price is $95.15. Amedisys, Inc. has a 1-year low of $89.55 and a 1-year high of $98.95. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.10. The business had revenue of $591.19 million for the quarter, compared to analysts’ expectations of $579.34 million. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. On average, equities research analysts predict that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.